天臣医疗(688013) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the first nine months decreased by 9.28% year-on-year, amounting to RMB 118,834,772.00[7] - Net profit attributable to shareholders decreased by 24.67% year-on-year, totaling RMB 26,072,007.42[7] - Basic and diluted earnings per share decreased by 25.86% to RMB 0.43[7] - Total profit for the first three quarters of 2020 was ¥30,079,904.22, a decline of 25.0% from ¥40,059,161.37 in the same period of 2019[28] - Net profit for Q3 2020 was ¥9,780,901.98, down 25.5% from ¥13,137,991.40 in Q3 2019[28] - The net profit for Q3 2020 was CNY 12,137,105.03, a decrease from CNY 13,099,014.95 in Q3 2019, representing a decline of approximately 7.4%[31] - The total profit for Q3 2020 was CNY 13,847,397.17, down from CNY 15,352,285.40 in Q3 2019, reflecting a decrease of about 9.8%[31] Asset and Equity Growth - Total assets increased by 287.03% year-on-year, reaching RMB 483,420,019.53[7] - Net assets attributable to shareholders increased by 326.40% year-on-year, totaling RMB 457,032,276.90[7] - Owner's equity surged to ¥457,032,276.90 compared to ¥107,184,821.57, marking a significant increase of approximately 326.5%[20] - Total assets increased to ¥483,420,019.53 from ¥124,905,957.67, representing a growth of approximately 286.5% year-over-year[19] - Cash and cash equivalents reached ¥263,505,445.67, up from ¥14,432,651.40, indicating a growth of approximately 1,726.5%[22] Cash Flow and Financing Activities - The company reported a net cash flow from operating activities of RMB 29,880,847.63, an increase of 11.69% year-on-year[7] - The company’s net cash flow from financing activities was ¥326,566,200.00, a significant recovery from a negative cash flow of -¥29,747,303.00 in the previous year[15] - The company raised CNY 342,794,200.00 through financing activities in Q3 2020, a significant increase compared to CNY 15,000,000.00 in Q3 2019[35] - Cash flow from operating activities for Q3 2020 was CNY 29,880,847.63, an increase from CNY 26,754,533.51 in Q3 2019, showing a growth of about 8.0%[34] Research and Development - The proportion of R&D investment to operating revenue increased by 1.02 percentage points to 8.51%[8] - Research and development expenses for Q3 2020 were ¥3,924,168.44, an increase of 14.8% compared to ¥3,417,491.60 in Q3 2019[27] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[47] Shareholder Information - The total number of shareholders reached 9,093 by the end of the reporting period[10] - The top two shareholders, Chen Wangyu and Chen Wangdong, each hold 26.17% of the shares, totaling 20,934,000 shares[10] Liabilities and Current Assets - Total liabilities increased to ¥10,233,985.17, a 166.36% rise from ¥3,842,222.71, mainly due to accrued but unpaid IPO issuance costs[13] - Current liabilities rose to ¥25,637,742.63 from ¥16,641,549.87, an increase of about 54.8%[19] - Total current assets reached ¥408,191,607.67, a substantial increase from ¥49,449,071.50, indicating strong liquidity[18] Inventory and Other Assets - Inventory increased to ¥24,038,613.19 from ¥23,466,724.30, a rise of about 2.4%[23] - The company reported a total non-current asset value of ¥75,228,411.86, slightly down from ¥75,456,886.17, a decrease of about 0.3%[19] - The company reported a significant inventory level of 23,466,724.30, indicating potential for future sales[44]